Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

LynFit Nutrition is a recurring segment featured on“CT BUZZ,” where Metabolic Weight Loss & Fat Burning Expert, Lisa Lynn, ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

"Nordic Cold Chain launches cold chain packaging for GLP-1 drugs" was originally created and published by Packaging Gateway, ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan Skrmetti.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...